- SteriPack is a global contract manufacturer of medical, pharmaceutical and diagnostic products
- The deal will support SteriPack’s growth plans as it engages in further M&A
- SteriPack made two acquisitions in 2021, buying HS Design and Halleck-Willard
Inflexion has led the buyout of global contract manufacturer SteriPack Group. The investment is being made via Buyout Fund VI, which closed on $3 billion in March. SteriPack serves the medical device, pharmaceutical and diagnostic markets. It provides outsourced design, development, manufacturing, assembly, packaging, sterilization and supply chain services. It has offices globally and a staff of over 650 employees.
“SteriPack is an extremely successful niche market player with a strong track record whose ongoing focus on high-quality innovation has earned it an impressive and loyal client roster,” said Flor Kassai, partner and head of Inflexion’s Buyout Fund. “We are incredibly excited to bring our experience to bear to help management accelerate its growth further across the globe.”
“We’re very proud of our strong growth record and are keen to build on it to take SteriPack even further as we become even more valued partners to our customers through expansion of our capabilities and geographic footprint,” said Andrew McLean, CEO of SteriPack. “Inflexion’s presence in our core markets of Europe, Asia and the US as well as its extensive M&A experience make it the ideal partner to support our future international growth.”
Inflexion is a middle-market private equity firm that backs both majority and minority investments. It typically looks to invest between $10 million to $500 million in equity in each deal. This deal will look to support SteriPack to engage in further M&A with the company having already made two acquisitions in 2021. It bought New Jersey-based HS Design in February 2021 and Colorado-based Halleck-Willard in October 2021.